Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANCOBON vs EXELDERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Treatment of systemic fungal infections (e.g., candidiasis, cryptococcosis) in combination with amphotericin B,Off-label: Serious infections caused by susceptible fungi
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Apply a thin layer to affected skin twice daily (morning and evening).
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (Cr Cl < 20 m L/min). Half-life correlates with creatinine clearance.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Deaminated to 5-fluorouracil in the body; further metabolized via same pathways as fluorouracil.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
2-4% bound to plasma proteins (albumin).
Not applicable; systemic levels are undetectable with topical use.
0.6-0.9 L/kg, indicating distribution into total body water. Penetrates well into cerebrospinal fluid (50-100% of serum levels), aqueous humor, and peritoneal fluid.
Not applicable; negligible systemic absorption.
Oral: 76-89% (well absorbed).
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: 50-100 mg/kg/day divided every 12-24 hours; GFR <10 m L/min: 50-100 mg/kg/day every 24-48 hours; intermittent hemodialysis: 50-100 mg/kg/day with each dialysis session; peritoneal dialysis: 50-100 mg/kg/day every 48 hours.
No dosage adjustment required for renal impairment.
No specific pediatric dosing based on Child-Pugh; use with caution and monitor liver function, potential reduced clearance. No standard adjustment defined.
No dosage adjustment required for hepatic impairment.
Weight-based: 50-150 mg/kg/day orally divided every 6 hours, or 50-150 mg/kg/day intravenously divided every 12 hours; neonates: 25-100 mg/kg/day intravenously divided every 12 hours.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
Start at lower end of dosing range (50 mg/kg/day), adjust based on renal function; monitor for hematologic toxicity.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
None.
None.
Hematologic toxicity (leukopenia, thrombocytopenia); renal impairment requires dose adjustment; hepatotoxicity; monitoring of blood counts and renal function recommended.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Hypersensitivity to flucytosine or any component.
Known hypersensitivity to sulconazole or any component of the formulation.
May be taken with food to reduce gastrointestinal upset. No specific dietary restrictions. Avoid alcohol.
None known.
Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly needed. Potential fetal risk in all trimesters. Contraindicated in first trimester unless life-threatening maternal infection.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Flucytosine is excreted into human breast milk; milk-to-plasma ratio approximately 1.0. Potential for serious adverse reactions in nursing infants; decision to discontinue nursing or drug depends on importance of drug to mother.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
Pregnancy may alter pharmacokinetics due to increased renal clearance and expanded plasma volume. Dose adjustment may be necessary; maintain serum concentrations within therapeutic range (trough 20-50 mcg/m L). Reduce dose in renal impairment, which may occur in pregnancy. No specific pregnancy dose guidelines; use with caution and monitor levels.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
Monitor for hepatotoxicity and bone marrow suppression; adjust dose in renal impairment (Cr Cl <50 m L/min requires dose interval extension). Obtain serum levels (desired peak 50-100 mcg/m L, trough <50 mcg/m L) to avoid toxicity. Use with caution in patients with pre-existing hematologic disorders or hepatic dysfunction. Synergistic with amphotericin B for cryptococcal meningitis; avoid concurrent use with nucleoside analogues (e.g., cytarabine) due to antagonism.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,May cause nausea and vomiting; taking with food can help.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe abdominal pain) or unusual bruising/bleeding immediately.,Avoid alcohol while on this medication.,Use effective contraception during treatment; notify your doctor if you become pregnant.,Regular blood tests are required to monitor blood counts and liver function.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANCOBON vs EXELDERM, answered by our medical review team.
ANCOBON is a Antifungal that works by Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.. EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANCOBON and EXELDERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANCOBON is: 50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.. The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANCOBON and EXELDERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANCOBON is classified as Category C. Flucytosine (ANCOBON) is teratogenic in animal studies, causing cleft palate, skeletal anomalies, and fetal resorption. Human data are limited; use in pregnancy only if clearly nee. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.